Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
- 21 August 1993
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 342 (8869), 462-464
- https://doi.org/10.1016/0140-6736(93)91593-b
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of InhibitorsNew England Journal of Medicine, 1993
- Incidence of development of factor VIII and factor IX inhibitors in haemophiliacsThe Lancet, 1992
- Complications of Hemophilia A Treatment: Factor VIII InhibitorsaAnnals of the New York Academy of Sciences, 1991
- Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia ANew England Journal of Medicine, 1990
- Antibody to Hepatitis G Mrus after a Vapour-Heated Factor Vlll GoncentrateThrombosis and Haemostasis, 1990
- Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrateThe Lancet, 1990
- SYMPTOMATIC PARVOVIRUS B19 INFECTION AND HEAT-TREATED FACTOR IX CONCENTRATEThe Lancet, 1989
- Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic HemophiliaNew England Journal of Medicine, 1989
- Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors)Human Pathology, 1987
- Characterization of the human factor VIII geneNature, 1984